Navigation Links
HEI, Inc. Initiates Delisting and Deregistration of Its Shares on NASDAQ
Date:12/7/2007

MINNEAPOLIS, Dec. 7 /PRNewswire-FirstCall/ -- HEI, Inc. (Nasdaq: HEII) (http://www.heii.com) announced today that it has voluntarily initiated the process of delisting its common stock from NASDAQ Capital Market and withdrawing its common stock from registration. The Company provided notice to the exchange on December 6, 2007 of its intent to withdraw its common stock from listing and registration on NASDAQ Capital Market, and anticipates that the last day of trading on the NASDAQ Capital Market will be Friday, December 14, 2007.

The Company plans to file a Form 25 with the Securities and Exchange Commission on December 17, 2007 to provide notice of its intention to withdraw its common stock from listing and registration under Section 12(d) of the Securities Act of 1933, as amended. The Company expects that the delisting will be effective 10 days after filing and the withdrawal of registration effective 90 days after filing. As a result of this filing, HEI's obligation to file certain reports and forms with the SEC, including Forms 10-K, 10-Q and 8-K, will be suspended on the effective date of delisting.

The Company believes that while the liquidity for its common stock may be reduced, the administrative and other economies and savings associated with delisting and deregistration are in the best interest of its shareholders. In addition, the Company believes that it would not be able to maintain NASDAQ listing for a number of reasons.

As a result of delisting and deregistration, the Company's securities will no longer be eligible for quotation on NASDAQ; however, the Company's securities may be eligible for quotation on the Pink Sheets (http://www.pinksheets.com) by broker-dealers. There can be no assurance, however, that any broker-dealer will make a market in the Company's common stock which would be required for Pink Sheet trading.

HEI, Inc. designs, develops and manufactures microelectronics, subsystems, systems, connectivity and software solutions for OEMs engaged for the medical equipment and medical device, hearing, communications, and industrial markets. HEI provides its customers with a single point of contact that can take an idea from inception to a fully functional, cost effective and manufacturability product utilizing innovative design solutions and by the application of state-of-the-art materials, processes and manufacturing capabilities.

Headquarters & Microelectronics Division

PO Box 5000, 1495 Steiger Lake Lane, Victoria, MN 55386

-- Advanced Medical Division

4801 North 63rd Street, Boulder, CO 80301

-- High Density Interconnect Division

610 South Rockford Drive, Tempe, AZ 85281

FORWARD LOOKING INFORMATION

Information in this news release, which is not historical, includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. You can identify these statements by forward-looking words such as "may," "will," "expect," "anticipate," "believe," "intend," "estimate," "continue," and similar words. Statements contained in this press release, including the implementation of business strategies, growth of specific markets, improved results and the estimated HEI revenue, cash flow and profits, expected cost savings from deregistering, are forward looking statements. All of such forward-looking statements involve risks and uncertainties including, without limitation, continuing adverse business and market conditions, the ability of HEI to secure and satisfy customers, the availability and cost of materials from HEI's suppliers, our ability to satisfy financial or other obligations or covenants set forth in our financing agreements, adverse competitive developments, change in or cancellation of customer requirements, collection of receivables and outstanding debt, HEI's ability to control fixed and variable operating expenses, and other risks detailed from time to time in HEI's SEC filings. We undertake no obligation to update these statements to reflect ensuing events or circumstances, or subsequent actual results. See the risk factor section in annual report on Form 10K for year ended September 1, 2007.


'/>"/>
SOURCE HEI, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
2. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
3. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
4. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
5. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
6. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
7. Harbinger Research Initiates Coverage on HearAtLast
8. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
9. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
10. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
11. Isolagen Initiates Phase III Clinical Program to Investigate Isolagen Therapy(TM) for the Treatment of Acne Scars
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 28, 2017 , ... Semrock’s highly popular SearchLight Spectra Viewer ... resource for fluorescence microscopists and optical system designers, enabling The Right Solution, Right ... the globe, SearchLight has become a tremendously popular tool for the fluorescence imaging ...
(Date:4/27/2017)... ... April 27, 2017 , ... Thinksport, the leaders in safe, ... award-winning sunscreen they’ve used the same scientific approach to solving smelly, sweaty athletes, ... the aisles that contain harmful chemicals that should be put nowhere near your ...
(Date:4/27/2017)... ... April 27, 2017 , ... Offering the purest product of its ... times purer and more potent than the market has seen before. Swissx uses proprietary ... well as a patented chromatography process for extraction, to produce its CBD oil--maximizing its ...
(Date:4/26/2017)... , ... April 26, 2017 , ... Journal of ... It can have severe consequences to overall dental health, including complications with speech, eating, ... turn to dental implants to replace lost teeth. As the number of tooth replacements ...
(Date:4/26/2017)... ... April 26, 2017 , ... The ... Excellence upon National Registry of Emergency Medical Technicians and welcomes this ... said Dr. Jan G. West, Ph.D. , CEO & Organizational Psychologist at ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... England , April 24, 2017 ... development, today announced the addition of a major ... ,Validated In-situ Plate Seeding,). The VIPS has been ... and 384 well microplates as part of the ... system offers a simple and more reliable solution ...
(Date:4/20/2017)... 2017 Research and Markets has ... and Market Prospects: Addressing Production Complexities Through Risk Management ... ... Biosimilar Pipeline and Market Prospects: Overcoming Production Complexities Through ... assessment of the current trends in the global biosimilars ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology: